Market Potential CarboCode operates in biotechnology with a focus on human sphingolipids for skin health, infant nutrition, and cognitive functioning, signaling cross‑sell opportunities across skincare and specialized infant nutrition segments as they scale production of gangliosides and human-identical milk lipids.

Expansion Readiness Recent and upcoming manufacturing capacity, including a 100 tons per year ganglioside facility in BioCant Park and €15M Series C funding, indicate readiness for commercial scale and potential partnerships with pharmaceutical, nutraceutical, and cosmetic OEMs seeking clinically backed lipid ingredients.

Clinical Evidence Investments in scientific and clinical evidence for benefits of human sphingolipids create a value proposition for premium, science‑backed products and enable sales conversations with brands pursuing differentiated skincare and infant nutrition claims.

Strategic Investors Series C funding led by Iberis Capital and a notable €15M investment signal strong investor validation, which can be leveraged to attract co‑development partners, grant opportunities, and larger multinational customers seeking reliable supply and R&D collaboration.

Geographic Synergy Dual‑site strategy with research in Germany and manufacturing in Portugal offers regional collaboration advantages, potential for EU‑based partnerships, and streamlined compliance for European customers targeting scale‑up and cost efficiency.